Based on the Exagen Inc stock forecast from 4 analysts, the average analyst target price for Exagen Inc is USD 6.75 over the next 12 months. Exagen Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Exagen Inc is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Exagen Inc’s stock price was USD 5.02. Exagen Inc’s stock price has changed by +23.65% over the past week, +40.22% over the past month and +137.91% over the last year.
No recent analyst target price found for Exagen Inc
No recent average analyst rating found for Exagen Inc
Frequently Asked Questions About Exagen Inc (XGN) Stock
Based on ratings from 4 analysts Exagen Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on XGN's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for XGN is USD 6.75 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on XGN's stock to indicate if its overvalued.
The last closing price of XGN's stock was USD 5.02.
Unfortunately we do not currently have any market capitalization data for XGN's stock.
Based on targets from 4 analysts, the average taret price for XGN is projected at USD 6.75 over the next 12 months.
This means that XGN's stock price may go up by +34.46% over the next 12 months.
We can't find any ETFs which contains Exagen Inc's stock.
Sorry, we do not have any data on the number of employees for Exagen Inc.
Sorry we do not have any infomation available on Exagen Inc's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Exagen Inc (XGN) Stock
Based on ratings from 4 analysts Exagen Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on XGN's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for XGN is USD 6.75 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on XGN's stock to indicate if its overvalued.
The last closing price of XGN's stock was USD 5.02.
Unfortunately we do not currently have any market capitalization data for XGN's stock.
Based on targets from 4 analysts, the average taret price for XGN is projected at USD 6.75 over the next 12 months.
This means that XGN's stock price may go up by +34.46% over the next 12 months.
We can't find any ETFs which contains Exagen Inc's stock.
Sorry, we do not have any data on the number of employees for Exagen Inc.
Sorry we do not have any infomation available on Exagen Inc's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for XGN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
